Sarepta Therapeutics | SRPT - Assets


Sarepta Therapeutics reported $3.18B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
Biogen USD 32.09B 2.6B Jun/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Capricor Therapeutics USD 326.28M 29.66M Mar/2026
Daiichi Sankyo JPY 4.11T 109.16B Jun/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
Incyte USD 7.87B 533.53M Jun/2026
Insmed USD 2.08B 188.7M Mar/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Moderna USD 10.96B 527M Jun/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Novavax USD 1.04B 133.35M Mar/2026
Pfizer USD 201.13B 6.49B Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 129.06B 1.04B Jun/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Tectonic Therapeutic USD 246.58M 14.46M Mar/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026